Egypt reserved doses of much-awaited Pfizer and Oxford trial vaccines, says Health minister

Ahram Online , Tuesday 10 Nov 2020

The secured quantities cover from 20% to 30% of the country's needs

Hala Zayed
Egypt's Health Minister Hala Zayed (R) during a scientific conference held on Tuesday, 10 November 2020. (photo courtesy of the Egyptian health ministry official Facebook page)

Egypt has reserved doses of a potential Coronavirus vaccine developed by the US Pfizer pharmaceutical corporation, which would cover up to 20 percent of the country's needs, Health Minister Hala Zayed in statement reported by local media on Tuesday.

Egypt has also secured doses of a promising British vaccine developed by Oxford University that will meet around 30 percent of the country's needs, the minister said.

According to the World Health Organization, there is no approved vaccine for the disease as of yet, which has so far killed 6,380 people and infected 109,422 others nationwide; and killed over one million people and infected more than 51 million others globally.

Both anticipated vaccines, which are still subject to trials, have reached advanced stages in many countries and show promising results.

On Monday, Pfizer claimed its experimental Coronavirus vaccine was more than 90% effective, revealing that up to 1.3 billion doses of the vaccine could be produced in 2021. While Oxford's vaccine, which has been shown in an early trial to prompt a protective immune response, is expected to be rolled out by the end of the year.

Minister Zayed, however, didn’t expand on the quantities of the reserved doses.

She added that as many as eleven Coronavirus vaccines have reached advanced stages, and Egypt is participating in the clinical trials of two of them.

In July, Egypt was selected by China to serve as a future African hub for manufacturing its possible Coronavirus vaccines, if Beijing develops one.

Trials of two China-made vaccines are being carried out in Egypt in cooperation with the Chinese government and other companies.

Short link: